UNSPSC 51271636: Ropivacaine hydrochloride monohydrate

This classification denotes an immunosuppressant with the molecular formula C17H26N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V910P86109, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-propyl-, monohydrochloride, (s)- but more generally known as ropivacaine hydrochloride, which bears US NIH Compound Identifier 175804. European Medicines Agency schedules Ropivacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04264MIG.

Most nations, for tariff and trade purposes, schedule ropivacaine hydrochloride monohydrate under HS 29333999 and SITC 51574. SMILES: CCCN1CCCC[C@H]1C(=O)NC2C(CCCC2C)C.O.CL.

UNSPSC 51271636 Ropivacaine hydrochloride monohydrate is a Commodity code covering a specific local anesthetic pharmaceutical product that state and local government health care and correctional facilities procure through cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is actively soliciting manufacturers and authorized pharmaceutical wholesalers to supply generic multi-source pharmaceuticals and over-the-counter products, including ropivacaine and related compounds, to participating state and local government facilities across multiple jurisdictions including Oregon. Suppliers must be cGMP-compliant, DSCSA-certified, and maintain active relationships with at least two of the three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with functioning chargeback systems in place. Vendors must maintain comprehensive insurance including $5 million commercial general liability per occurrence, submit pricing in fixed-price, net-price (NF30, NF60, NF90), or WAC-minus formats, and carry inventory with expiration dates at least one year from manufacture and a minimum six-month shelf life. Evaluation emphasizes price competitiveness (75 percent weight), with additional scoring on fixed pricing, administrative compliance, EDI capability, and willingness to accept MMCAP's 3 percent administrative fee.

MMCAP's RFP for generic multi-source pharmaceuticals represents the primary recent activity under this code and reflects procurement across multiple state and local government health care systems, including hospital networks and correctional facilities in Minnesota and Oregon. The solicitation issued January 20, 2026 with proposals due March 26, 2026, targets an effective contract date of July 1, 2026 with a two-year initial term and optional extensions. No specific award value or budget range is disclosed, but vendors should anticipate performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Submissions are made through the ePro procurement system with pricing and product information in designated CSV format and supporting documentation emailed to MMCAP_Infuse.RFP@state.mn.us. The sourcing structure—establishing multiple contract awards based on therapeutic considerations, product availability, and patient safety—creates opportunities for manufacturers willing to work through authorized wholesaler networks and comply with the administrative and compliance infrastructure MMCAP requires.